Action Autolus Therapeutics - AUTL

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

1,96

Prix Achat

1,92

Prix Vente

2,04

Volume échangé

1 048 378

1,93 Fourchette du Jour 2,01

0,00 Plage de 52 semaines 0,00

Cap du marché

521,599M

Clôture Veille

1,95

Ouverture

1,98

Dernière Transaction

1.98

Dernière heure de transaction

Volume financier

US$ 2 062 411

VWAP

1,9672

Volume moyen (3 m)

Actions en circulation

266 121 689

Rendement du Dividende

Ratio Cours sur Bénéfices

-2,50

Bénéfice par action (BPA)

-0,78

Chiffre d'affairess

1,7M

Bénéfice net

-208,38M

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.autolus.com

Siège social

London, Gbr

Fondé

Autolus Therapeutics PLC est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker AUTL. Le dernier cours de clôture d'Autolus Therapeutics était de US$1,95. Au cours de la dernière année, les actions de Autolus Therapeutics ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Autolus Therapeutics compte actuellement 266 121 689 actions en circulation. La capitalisation boursière d'Autolus Therapeutics est de US$518,94 million. Autolus Therapeutics a un ratio cours/bénéfice (ratio PE) de -2.50.

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage...

Autolus Therapeutics Provides Business Updates and 2025 Overview

- Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January...

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage...

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

AUTL - Frequently Asked Questions (FAQ)

What is the current Autolus Therapeutics share price?

The current share price of Autolus Therapeutics is US$ 1,96

How many Autolus Therapeutics shares are in issue?

Autolus Therapeutics has 266 121 689 shares in issue

What is the market cap of Autolus Therapeutics?

The market capitalisation of Autolus Therapeutics is USD 518,94M

What is the 1 year trading range for Autolus Therapeutics share price?

Autolus Therapeutics has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of Autolus Therapeutics?

The price to earnings ratio of Autolus Therapeutics is -2,5

What is the cash to sales ratio of Autolus Therapeutics?

The cash to sales ratio of Autolus Therapeutics is 306,25

What is the reporting currency for Autolus Therapeutics?

Autolus Therapeutics reports financial results in USD

What is the latest annual turnover for Autolus Therapeutics?

The latest annual turnover of Autolus Therapeutics is USD 1,7M

What is the latest annual profit for Autolus Therapeutics?

The latest annual profit of Autolus Therapeutics is USD -208,38M

What is the registered address of Autolus Therapeutics?

The registered address for Autolus Therapeutics is 191 WOOD LANE, LONDON, W12 7FP

What is the Autolus Therapeutics website address?

The website address for Autolus Therapeutics is www.autolus.com

Which industry sector does Autolus Therapeutics operate in?

Autolus Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MLGOMicroAlgo Inc	US$ 6,3767 (454,50%)	531,54M
BOXLBoxlight Corporation	US$ 3,1099 (51,70%)	1,84M
GDEVGDEV Inc	US$ 20,90 (46,56%)	264,44k
IVVDInvivyd Inc	US$ 1,7501 (44,64%)	37,75M
UPCUniverse Pharmaceuticals Inc	US$ 0,2003 (40,56%)	420,21M
DOYUDouYu International Holdings Ltd	US$ 7,19 (-55,31%)	1,28M
MNDRMobile health Network Solutions	US$ 0,5048 (-46,29%)	18,61M
BLUEbluebird bio Inc	US$ 4,09 (-41,90%)	5,44M
GCLGCL Global Holdings Ltd	US$ 3,83 (-31,48%)	635,26k
AXTIAXT Inc	US$ 1,57 (-31,44%)	6,66M
MLGOMicroAlgo Inc	US$ 6,3767 (454,50%)	531,54M
UPCUniverse Pharmaceuticals Inc	US$ 0,2003 (40,56%)	420,21M
ADTXAditxt Inc	US$ 0,0922 (-22,39%)	278,25M
NVDANVIDIA Corporation	US$ 134,43 (-4,05%)	228,15M
HOLOMicroCloud Hologram Inc	US$ 1,565 (31,51%)	190,81M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Autolus Therapeutics PLC (AUTL)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Autolus Therapeutics PLC

AUTL Dernières nouvelles

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Autolus Therapeutics Provides Business Updates and 2025 Overview

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Autolus Therapeutics Provides Business Updates and 2025 Overview

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

AUTL - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Autolus Therapeutics PLC (AUTL) Cours

Autolus Therapeutics PLC (AUTL)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Autolus Therapeutics PLC

AUTL Dernières nouvelles

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Autolus Therapeutics Provides Business Updates and 2025 Overview

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Autolus Therapeutics Provides Business Updates and 2025 Overview

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

AUTL - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR